Cefditoren
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Cefditoren: From Bacterial Infections to Rheumatoid Arthritis
One-Sentence Summary
Cefditoren is a third-generation cephalosporin antibiotic. The TxGNN model predicts it may be effective for rheumatoid arthritis, but this is a model prediction only, with 0 clinical trials and 0 publications supporting it. No biological rationale for this link has been established.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the licence records compiled for this report (approved indication text is empty) |
| Predicted New Indication | Rheumatoid arthritis |
| TxGNN Prediction Score | 0.9902 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (5 of 5) – CDSCO approval status is not included in this data |
| Number of Listed Products | 5 (valid: 5) |
| Number of Approvals | 5 single-ingredient licences |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the data compiled for this report. Based on general pharmacology, cefditoren is a third-generation cephalosporin (given as a pivoxil prodrug) that inhibits bacterial cell wall synthesis by binding penicillin-binding proteins.
There is no established mechanistic link to rheumatoid arthritis. Cefditoren has no known immunomodulatory or anti-inflammatory activity relevant to the disease pathways involved (e.g., TNF, IL-6, JAK/STAT, B/T-cell signalling). The high TxGNN score of 0.9902 is a TxGNN model (deep learning) prediction and most likely reflects network proximity or shared neighbours rather than biological evidence. Therefore, the prediction should be treated as a hypothesis only, not as a reasonable therapeutic direction at this time.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 246583 | Zostum O 100mg Dry Syrup | Bottle of 30 ml dry syrup | Not stated |
| 38267 | Cefdicare 200mg Tablet | Strip of 10 tablets | Not stated |
| 37725 | Ceftorin 200mg Tablet | Strip of 6 tablets | Not stated |
| 246413 | Zostum-O 200mg Tablet | Strip of 10 tablets | Not stated |
| 247093 | Zostum-O 50mg Tablet DT | Strip of 10 dispersible tablets | Not stated |
Safety Considerations
- Drug Interactions: 27 interactions were recorded in total; 20 are listed in the data compiled for this report, all of Moderate level. Main ones include:
- Acid-reducing agents: famotidine, ranitidine, cimetidine, nizatidine, and proton pump inhibitors (omeprazole, esomeprazole, lansoprazole, dexlansoprazole, rabeprazole, pantoprazole)
- Antacids and alkalinising agents: aluminium hydroxide, calcium carbonate, magaldrate, magnesium carbonate/hydroxide/oxide, sodium citrate, sodium bicarbonate
- Anticoagulant: dicoumarol
- Cefditoren is a pivoxil prodrug, and carnitine depletion is a recognised safety consideration.
Please refer to the package insert for warnings and contraindications, as these were not available in the data compiled for this report.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction rests only on a TxGNN model (deep learning) score. There are no clinical trials or publications on cefditoren in rheumatoid arthritis, and no plausible mechanistic link to the disease. Evidence level is L5.
To proceed, the following is needed:
- Mechanism of action data and any plausible biological link to rheumatoid arthritis pathways
- Preclinical or exploratory studies directly addressing the disease
- Package insert warnings and contraindications, including approved indication text for the Indian licences
- Assessment of route compatibility and whether long-term dosing would be safe (e.g., carnitine depletion)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.